C3 and dry age related macular degeneration: In particular, RORA is implicated in AMD and is a key regulator of pathways perturbed in AMD disease, such as the complement system including complement C3 and C5 that are targets of recent FDA-approved drugs for dry AMD [27, 28, 46, 47].